These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16757970)

  • 21. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
    Massaro AM
    Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
    [No Abstract]   [Full Text] [Related]  

  • 23. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
    Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical pharmacology of zoledronic acid.
    Green JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):3-11. PubMed ID: 12584689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
    Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
    Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
    Lipton A; Campbell-Baird C; Harvey H; Kim C; Demers L; Costa L
    Am J Clin Oncol; 2010 Feb; 33(1):75-8. PubMed ID: 19652577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumor activity of zoledronic acid].
    Tamási L
    Magy Onkol; 2009 Sep; 53(3):269-71. PubMed ID: 19793692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapies of bone disease with bisphosphonates.
    Syddall SP; Ottewell PD; Holen I
    Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
    Brown HK; Holen I
    Curr Cancer Drug Targets; 2009 Nov; 9(7):807-23. PubMed ID: 20025569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.